Processa Pharmaceuticals Earnings Estimate
| PCSA Stock | USD 3.14 0.05 1.57% |
Processa Pharmaceuticals Earnings Estimation Breakdown
The calculation of Processa Pharmaceuticals' earning per share is based on the data from the past 12 consecutive months, used for reporting the company's financial figures. The next projected EPS of Processa Pharmaceuticals is estimated to be -2.6875 with the future projection ranging from a low of -2.6875 to a high of -2.6875. Please be aware that this consensus of annual earnings estimates for Processa Pharmaceuticals is based on EPS before non-recurring items and includes expenses related to employee stock options.Last Reported EPS
-2.69 Lowest | Expected EPS | -2.69 Highest |
Processa Pharmaceuticals Earnings Projection Consensus
Suppose the current estimates of Processa Pharmaceuticals' value are higher than the current market price of the Processa Pharmaceuticals stock. In this case, investors may conclude that Processa Pharmaceuticals is overpriced and will exhibit bullish sentiment. On the other hand, if the present value is lower than the stock price, analysts may conclude that the market undervalues the equity. These scenarios may suggest that the market is not as efficient as it should be at the estimation time, and Processa Pharmaceuticals' stock will quickly adjusts to the new information provided by the consensus estimate.
| Number of Analysts | Historical Accuracy | Last Reported EPS | Estimated EPS for 31st of December 2025 | Current EPS (TTM) | |
| 2 | 50.0% | -0.07 | -2.6875 | -28.75 |
Processa Pharmaceuticals Earnings per Share Projection vs Actual
Actual Earning per Share of Processa Pharmaceuticals refers to what the company shows during its earnings calls or quarterly reports. The Expected EPS is what analysts covering Processa Pharmaceuticals predict the company's earnings will be in the future. The higher the earnings per share of Processa Pharmaceuticals, the better is its profitability. While calculating the Earning per Share, we use the weighted ratio, as the number of shares outstanding can change over time.Processa Pharmaceuticals Estimated Months Earnings per Share
For an investor who is primarily interested in generating an income out of investing in entities such as Processa Pharmaceuticals, the EPS ratio can tell if the company is intending to increase its current dividend. Although EPS is an essential tool for investors, it should not be used in isolation. EPS of Processa Pharmaceuticals should always be considered in relation to other companies to make a more educated investment decision.Processa Quarterly Analyst Estimates and Surprise Metrics
Earnings surprises can significantly impact Processa Pharmaceuticals' stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2025-11-06 | 2025-09-30 | -0.45 | -0.07 | 0.38 | 84 | ||
2025-08-11 | 2025-06-30 | -0.23 | -0.25 | -0.02 | 8 | ||
2025-05-08 | 2025-03-31 | -1.18 | -0.3 | 0.88 | 74 | ||
2025-03-27 | 2024-12-31 | -0.92 | -0.74 | 0.18 | 19 | ||
2024-10-30 | 2024-09-30 | -1 | -1.03 | -0.03 | 3 | ||
2024-08-13 | 2024-06-30 | -0.98 | -1.01 | -0.03 | 3 | ||
2024-05-10 | 2024-03-31 | -1.18 | -1.11 | 0.07 | 5 | ||
2024-03-29 | 2023-12-31 | -1.6 | -1.7 | -0.1 | 6 | ||
2023-11-13 | 2023-09-30 | -0.1 | -0.08 | 0.02 | 20 | ||
2023-08-10 | 2023-06-30 | -0.23 | -0.097 | 0.133 | 57 | ||
2023-05-15 | 2023-03-31 | -0.28 | -0.18 | 0.1 | 35 | ||
2023-03-30 | 2022-12-31 | -0.32 | -0.36 | -0.04 | 12 | ||
2022-11-08 | 2022-09-30 | -0.34 | -0.37 | -0.03 | 8 | ||
2022-08-11 | 2022-06-30 | -0.2 | -0.32 | -0.12 | 60 | ||
2022-05-12 | 2022-03-31 | -0.21 | -0.2 | 0.01 | 4 | ||
2022-03-30 | 2021-12-31 | -0.19 | -0.21 | -0.02 | 10 | ||
2021-11-11 | 2021-09-30 | -0.18 | -0.19 | -0.01 | 5 | ||
2021-08-12 | 2021-06-30 | -0.14 | -0.2 | -0.06 | 42 | ||
2021-05-13 | 2021-03-31 | -0.1 | -0.14 | -0.04 | 40 | ||
2021-03-25 | 2020-12-31 | -0.35 | -1.69 | -1.34 | 382 | ||
2020-11-12 | 2020-09-30 | -0.16 | -0.55 | -0.39 | 243 |
About Processa Pharmaceuticals Earnings Estimate
The earnings estimate module is a useful tool to check what professional financial analysts are assuming about the future of Processa Pharmaceuticals earnings. We show available consensus EPS estimates for the upcoming years and quarters. Investors can also examine how these consensus opinions have evolved historically. We show current Processa Pharmaceuticals estimates, future projections, as well as estimates 1, 2, and three years ago. Investors can search for a specific entity to conduct investment planning and build diversified portfolios. Please note, earnings estimates provided by Macroaxis are the average expectations of expert analysts that we track. If a given stock such as Processa Pharmaceuticals fails to match professional earnings estimates, it usually performs purely. Wall Street refers to that as a 'negative surprise.' If a company 'beats' future estimates, it's usually called an 'upside surprise.'
Please read more on our stock advisor page.| Last Reported | Projected for Next Year | ||
| Retained Earnings | -78.5 M | -74.6 M | |
| Retained Earnings Total Equity | -22.9 M | -21.7 M | |
| Earnings Yield | (5.04) | (4.79) | |
| Price Earnings Ratio | (0.21) | (0.22) |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.When determining whether Processa Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Processa Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Processa Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Processa Pharmaceuticals Stock:Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Processa Pharmaceuticals. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in main economic indicators. For information on how to trade Processa Stock refer to our How to Trade Processa Stock guide.You can also try the Stock Tickers module to use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Processa Pharmaceuticals. Anticipated expansion of Processa directly elevates investor willingness to pay premium valuations. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive Processa Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Investors evaluate Processa Pharmaceuticals using market value (trading price) and book value (balance sheet equity), each telling a different story. Calculating Processa Pharmaceuticals' intrinsic value—the estimated true worth—helps identify when the stock trades at a discount or premium to fair value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. External factors like market trends, sector rotation, and investor psychology can cause Processa Pharmaceuticals' market price to deviate significantly from intrinsic value.
It's important to distinguish between Processa Pharmaceuticals' intrinsic value and market price, which are calculated using different methodologies. Investment decisions regarding Processa Pharmaceuticals should consider multiple factors including financial performance, growth metrics, competitive position, and professional analysis. Conversely, Processa Pharmaceuticals' market price signifies the transaction level at which participants voluntarily complete trades.